Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020
Authors: Jessica L. Prince-Guerra, Olivia Almendares, Leisha D. Nolen, Jayleen K. L. Gunn, Ariella P. Dale, Sean A. Buono, Molly Deutsch-Feldman, Suganthi Suppiah, LiJuan Hao, Yan Zeng, Valerie A. Stevens, Kristen Knipe, Justine Pompey, Christine Atherstone, David P. Bui, Tracy Powell, Azaibi Tamin, Jennifer L. Harcourt, Patricia L. Shewmaker, Magdalena Medrzycki, Phili Wong, Shilpi Jain, Alexandra Tejada-Strop, Shannon Rogers, Brian Emery, Houping Wang, Marla Petway, Caitlin Bohannon, Jennifer M. Folster, Adam MacNeil, Reynolds Salerno, Wendi Kuhnert-Tallman, Jacqueline E. Tate, Natalie J. Thornburg, Hannah L. Kirking, Khalilullah Sheiban, Julie Kudrna, Theresa Cullen, Kenneth K. Komatsu, Julie M. Villanueva, Dale A. Rose, John C. Neatherlin, Mark Anderson, Paul A. Rota, Margaret A. Honein, William A. Bower
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Rapid antigen tests, such as the Abbott BinaxNOW COVID-19 Ag Card (BinaxNOW), offer results more rapidly (approximately 15-30 minutes) and at a lower cost than do highly sensitive nucleic acid amplification tests (NAATs) (1). Rapid antigen tests have received Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for use in symptomatic persons (2), but data are lacking on test performance in asymptomatic persons to inform expanded screening testing to rapidly identify and isolate infected persons (3). To evaluate the performance of the BinaxNOW rapid antigen test, it was used along with real-time reverse transcription-polymerase chain reaction (RT-PCR) testing to analyze 3,419 paired specimens collected from persons aged ≥10 years at two community testing sites in Pima County, Arizona, during November 3-17, 2020. Viral culture was performed on 274 of 303 residual real-time RT-PCR specimens with positive results by either test (29 were not available for culture). Compared with real-time RT-PCR testing, the BinaxNOW antigen test had a sensitivity of 64.2% for specimens from symptomatic persons and 35.8% for specimens from asymptomatic persons, with near 100% specificity in specimens from both groups. Virus was cultured from 96 of 274 (35.0%) specimens, including 85 (57.8%) of 147 with concordant antigen and real-time RT-PCR positive results, 11 (8.9%) of 124 with false-negative antigen test results, and none of three with false-positive antigen test results. Among specimens positive for viral culture, sensitivity was 92.6% for symptomatic and 78.6% for asymptomatic individuals. When the pretest probability for receiving positive test results for SARS-CoV-2 is elevated (e.g., in symptomatic persons or in persons with a known COVID-19 exposure), a negative antigen test result should be confirmed by NAAT (1). Despite a lower sensitivity to detect infection, rapid antigen tests can be an important tool for screening because of their quick turnaround time, lower costs and resource needs, high specificity, and high positive predictive value (PPV) in settings of high pretest probability. The faster turnaround time of the antigen test can help limit transmission by more rapidly identifying infectious persons for isolation, particularly when used as a component of serial testing strategies.